Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claim 1 is currently pending and is the subject of this Office Action. This is the first Office Action on the merits of the claims.
Information Disclosure Statement
The information disclosure statements (IDSs) submitted on 08/06/2024 are in compliance with the provisions of 37 CFR 1.97 and have been considered.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 1 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection.
Independent claim 1 is directed to an isolated antibody that binds to human Jagged1, wherein the antibody comprises an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 55 or 59, wherein X is any amino acid other than S. Although the claim does not include the other five HVRs or CDRs in addition to the recited HVR-H3, the specification describes Jagged1 antibodies with both the heavy chain and light chain variable region sequences. On page 65, Table 2, the specification presents antibodies A, A-1, A-2, which are described as having heavy chain and light chain variable region sequences: “The heavy chain and light chain variable region sequences for antibody A-1 are shown in SEQ ID NOs: 17 and 18, respectively. The heavy chain and light chain variable region sequences for antibody A-2 are shown in SEQ ID NOs: 25 and 26, respectively” (p. 65, under Table 2). Thus, the antibodies that bind to human Jagged1 in the specification have a full heavy chain and a full light chain. No examples of other antibodies that bind Jagged1 with only the HVR-H3 are provided.
Furthermore, considering that there are 20 amino acids, the specification does not seem to define 19 HVR-H3 structures in which X of SEQ ID NO: 55 is any amino acid other than S nor does the specification define 19 HVR-H3 structures in which X is any amino acid other than S.
To provide evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. Applicant is directed to MPEP 2163 for guidelines on compliance with the written description requirement.
Here, applicant has not described a reasonable number of agents capable of binding human Jagged1, i.e. the required starting materials for the claims, but rather, applicant has presented the public with an idea of how to perform an assay that might identify some agents that fall within the scope of the claim. Of course, depending on what agents are used in the screening assay, it may well identify none. The Court of Appeals for the Federal Circuit addressed claims of this sort in great detail in University of Rochester v. G.D. Searle and Co. (69 USPQ 2nd 1886, CAFC 2004). In Rochester, the Federal Circuit upheld the district court's ruling that patent claims which recited administration of compounds not disclosed, but rather to be identified in a screening assay, were invalid on their face. Here the claimed agent (antibody) does not have any particular conserved structure. Moreover, the specification does not disclose a structure/function correlation. Agents claimed with no structure that are only defined by function are generally not considered described.
Functionally defined genus claims can be inherently vulnerable to invalidity challenge for lack of written description support, especially in technology fields that are highly unpredictable, where it is difficult to establish a correlation between structure and function for the whole genus or to predict what would be covered by the functionally claimed genus. Abbvie Deutschland GMBH & Co. v. Janssen Biotech, Inc. (759 F.3d 1285 (Fed. Cir. 2014). “When a patent claims a genus using functional language to define a desired result, the specification must demonstrate that the applicant has made a generic invention that achieves the claimed result and do so by showing that the applicant has invented species sufficient to support a claim to the functionally-defined genus." Capon v. Eshhar, 418 F.3d 1349 (Fed. Cir. 2005).
Consequently, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus of administered agents nor guidance as to which of the myriad of molecules encompassed by the instant method claims would meet the limitations of the claims.
Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111 (Fed. Cir. 1991), clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 1116).
Furthermore, in Amgen Inc. et al. v. Sanofi et al., 598 U.S. 594, 2023 USPQ2d 602 (2023), the
Supreme Court, held that claims drawn to a genus of monoclonal antibodies, which were functionally claimed by their ability to bind to a specific protein, PCSK9, were invalid due to lack of enablement. The claims at issue were functional, in that they defined the genus by its function (the ability to bind to specific residues of PCSK9) as opposed to reciting a specific structure (the amino acid sequence of the antibodies in the genus). See MPEP 2164.01.
In the present claim 1, the antibody is only defined by functional properties, its ability to bind human Jagged1, with no specific structure recited in the claim. In view of the fact patterns detailed in Amgen Inc. et al. v. Sanofi et al., the applicant is not in possession of an antibody that binds to human Jagged1 of claim 1 that is enabled.
The skilled artisan cannot envision the detailed chemical structure of the genus of claimed treatment agents, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of identification. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See Fiers v. Revel, 25 USPQ2d 1601 at 1606 (CAFC 1993) and Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016 (Fed. Cir. 1991). Therefore, the instant claims do not meet the written description requirement.
Claim 1 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
Scope of Enablement
Claim 1 is rejected under 35 U.S.C. 112(a) because, the claim recites an isolated antibody that binds to human Jagged1, wherein the antibody comprises an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 55 or 59, wherein X is any amino acid other than S, and thus the claim requires only one HVR/CDR. The claim does not require all the HVR/CDRs. However, the HVRs/CDRs confer specificity and function to an antibody, and isolated antibody without all six specific HVRs/CDRs may not bind Jagged1 and function as claimed.
In this regard, the application disclosure and claims have been compared per the factors indicated in the decision In re Wands, 8 USPQ 2d 1400 (Fed. Cir., 1988) as to undue experimentation. The factors include:
1) the nature of the invention;2) the scope or breadth of the claims;3) the state of the prior art;4) the predictability or unpredictability of the art; 5) the relative skill of those skilled in the art; 6) the presence or absence of working examples; 7) the amount of direction or guidance presented and,8) the quantity of experimentation necessary.
The relevant factors are addressed below on the basis of comparison of the disclosure, the claims and the state of the prior art in the assessment of undue experimentation.
Scope or breadth of the claims: Independent claim 1 recites:
1. (Original) An isolated antibody that binds to human Jagged1, wherein the antibody comprises an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 55 or 59, wherein X is any amino acid other than S.
According to the present specification, HVRs are CDRs (p. 20, line 9 and lines 14 – 17).
Because claim 1 recites only HVR-H3 without the other five HVRs (HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2), not all the HVRs are required. Furthermore, HVR-H3 may have 38 different structures that are not supported by the present specification (see discussion above). Because claim 1 requires that the recited antibody bind human Jagged1 and HVRs/CDRs confer function and specificity to the antibody, the antibody as claimed (without the appropriate HVRs/CDRs) may not be capable of binding as claimed. The present specification as originally filed lacks adequate guidance, direction, or discussion to apprise the skilled artisan of specific antibodies capable of binding human Jagged1 but do(es) not require all six HVRs. The specification does not provide explanation regarding anti-Jagged1 antibodies without all the disclosed HVRs (or any significant identity with said HVRs) that are capable of binding human Jagged1.
Degree of predictability or unpredictability in the art: As taught by CHEN (Chen C. et al. Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. EMBO J. 1995 Jun 15;14(12):2784-94; see PTO-892: Notice of References Cited), random point mutations in the amino acids of the CDRs of an antibody can result in significant effects to the structure and function of the antibody (see Discussion, p. 2789). Thus, the level of unpredictability in the art is high, especially since the claims do not require all six HVRs/CDRs.
Relative skill possessed by those in the art: In view of the state and complexity of the prior art, and the scope of the claims, which are drawn to an isolated antibody that binds to human Jagged1, the level of skill in the art is high and is at least that of a medical doctor or Ph.D. scientist with several years of experience in the fields of antibody or antibody engineering and/or immunotherapy.
Presence or absence of working examples: The specification does not provide examples that define the effects resulting from the alterations of the HVRs/CDRs of the claimed polypeptide. Nor does the specification provide any examples of sequences lacking significant sequence identity with the disclosed HVRs/CDRs (e.g., those of Abs A, A-1 and A-2, which are shown to bind human Jagged1 in Table 2, p. 65 of the specification and whose HVRs are disclosed in FIGs 4A-1 – 4B). No examples are provided of derivatives lacking all six HVRs/CDRs.
Amount of guidance or direction provided/Quantity of experimentation required: The specification only provides guidance regarding the effects of antibodies that bind to human Jagged1 with specific HVRs/CDRs and does not include any direction on how to prepare antibodies or derivatives thereof lacking all six HVRs/CDRs that still function as claimed. In the absence of working examples, undue experimentation would be necessary to determine the structure and scope of those polypeptides (if any) that fall within the bounds of the claim, but which lack significant sequence identity with the specific HVR/CDR sequences disclosed, and/or that lack all six HVRs/CDRs.
Conclusion: In summary, the claim does not require all six HVRs/CDRs on the claimed antibody and thus contain subject matter which is not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 – 38 of U.S. Patent No. 9,518,121.
Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims recite an isolated antibody that binds to human Jagged1, wherein the antibody comprises an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 55 or 59, wherein X is any amino acid other than S.
Patented SEQ ID NOs: 33, 37, 51 – 52 and 54 – 57 each discloses the sequence of SEQ ID NO: 55 or a sequence wherein X of SEQ ID NO: 55 is any amino acid other than S with 100% identity. See Appendix. Patented SEQ ID NOs: 58 - 59, 62, 64 – 68, 69 – 70 and 79 – 80 each discloses the sequence of SEQ ID NO: 59 or a sequence wherein X of SEQ ID NO: 59 is any amino acid other than S.
Thus, the patented claims anticipate present claim 1.
Conclusion
Claim 1 is not allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Estella Gustilo whose telephone number is (703)756-1706. The examiner can normally be reached Monday - Friday 9:30 AM - 5:30 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory Emch can be reached at 571-272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ESTELLA M. GUSTILO/Examiner, Art Unit 1646
/PETER J REDDIG/Primary Examiner, Art Unit 1646
APPENDIX
Alignment with SEQ ID NO: 55 or SEQ ID NO: 55 wherein wherein X is any amino acid other than S.
US-14-619-930-33
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 33, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 33
LENGTH: 116
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-1(S101T) heavy chain variable region
Query Match 100.0%; Score 31; Length 116;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXLFAY 7
|| ||||
Db 99 AGTLFAY 105
US-14-619-930-37
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 37, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 37
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-1(S101T) HVR-H3
Query Match 100.0%; Score 31; Length 7;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXLFAY 7
|| ||||
Db 1 AGTLFAY 7
US-14-619-930-51
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 51, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 51
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-1(S101T) IgG1 heavy chain
Query Match 100.0%; Score 31; Length 446;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXLFAY 7
|| ||||
Db 99 AGTLFAY 105
US-14-619-930-52
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 52, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 52
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-1(S101T) IgG1 heavy chain N297G
Query Match 100.0%; Score 31; Length 446;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXLFAY 7
|| ||||
Db 99 AGTLFAY 105
US-14-619-930-54
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 54, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 54
LENGTH: 116
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-1(S101X) heavy chain variable region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (101)..(101)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 96.8%; Score 30; Length 116;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXLFAY 7
|||||||
Db 99 AGXLFAY 105
US-14-619-930-55
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 55, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 55
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-1(S101X) HVR-H3
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 96.8%; Score 30; Length 7;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXLFAY 7
|||||||
Db 1 AGXLFAY 7
US-14-619-930-56
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 56, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 56
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-1(S101X) IgG1 heavy chain
FEATURE:
NAME/KEY: misc_feature
LOCATION: (101)..(101)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 96.8%; Score 30; Length 446;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXLFAY 7
|||||||
Db 99 AGXLFAY 105
US-14-619-930-57
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 57, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 57
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-1(S101X) IgG1 heavy chain N297G
FEATURE:
NAME/KEY: misc_feature
LOCATION: (101)..(101)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 96.8%; Score 30; Length 446;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXLFAY 7
|||||||
Db 99 AGXLFAY 105
Alignment with SEQ ID NO: 59 or SEQ ID NO: 59 wherein wherein X is any amino acid other than S.
US-14-619-930-58
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 58, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 58
LENGTH: 116
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A(S101X) heavy chain variable region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (101)..(101)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 97.4%; Score 37; Length 116;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|||||||
Db 99 AGXWFAY 105
US-14-619-930-59
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 59, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 59
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A(S101X) HVR-H3; Antibody A-2(S101X) HVR-H3
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(3)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 97.4%; Score 37; Length 7;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|||||||
Db 1 AGXWFAY 7
US-14-619-930-62
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 62, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 62
LENGTH: 116
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-2(S101X) heavy chain variable region
FEATURE:
NAME/KEY: misc_feature
LOCATION: (101)..(101)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 97.4%; Score 37; Length 116;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|||||||
Db 99 AGXWFAY 105
US-14-619-930-64
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 64, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 64
LENGTH: 7
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A(S101T) HVR-H3; Antibody A-2(S101T) HVR-H3
Query Match 100.0%; Score 38; Length 7;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|| ||||
Db 1 AGTWFAY 7
US-14-619-930-65
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 65, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 65
LENGTH: 116
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A(S101T) heavy chain variable region
Query Match 100.0%; Score 38; Length 116;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|| ||||
Db 99 AGTWFAY 105
US-14-619-930-66
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 66, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 66
LENGTH: 116
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-2(S101T) heavy chain variable region
Query Match 100.0%; Score 38; Length 116;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|| ||||
Db 99 AGTWFAY 105
US-14-619-930-67
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 67, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 67
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A(S101X) IgG1 heavy chain N297G
FEATURE:
NAME/KEY: misc_feature
LOCATION: (101)..(101)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 97.4%; Score 37; Length 446;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|||||||
Db 99 AGXWFAY 105
US-14-619-930-68
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 68, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 68
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-2(S101X) IgG1 heavy chain N297G
FEATURE:
NAME/KEY: misc_feature
LOCATION: (101)..(101)
OTHER INFORMATION: Xaa can be any amino acid other than Ser
Query Match 97.4%; Score 37; Length 446;
Best Local Similarity 100.0%;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|||||||
Db 99 AGXWFAY 105
US-14-619-930-69
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 69, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 69
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A(S101T) IgG1 heavy chain N297G
Query Match 100.0%; Score 38; Length 446;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|| ||||
Db 99 AGTWFAY 105
US-14-619-930-70
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 70, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 70
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-2(S101T) IgG1 heavy chain N297G
Query Match 100.0%; Score 38; Length 446;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|| ||||
Db 99 AGTWFAY 105
US-14-619-930-79
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 79, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 79
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A(S101T) IgG1 heavy chain
Query Match 100.0%; Score 38; Length 446;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|| ||||
Db 99 AGTWFAY 105
US-14-619-930-80
(NOTE: this sequence has 3 duplicates in the database searched.
See complete list at the end of this report)
Sequence 80, US/14619930
Patent No. 9518121
GENERAL INFORMATION
APPLICANT: GENENTECH, INC.
APPLICANT: SIEBEL, Christian W.
APPLICANT: WU, Yan
APPLICANT: HANG, Julie Q.
APPLICANT: CHINN, Yvonne
TITLE OF INVENTION: ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE
FILE REFERENCE: GENE-33748/US-1/PRO
CURRENT APPLICATION NUMBER: US/14/619,930
CURRENT FILING DATE: 2015-02-11
PRIOR APPLICATION NUMBER: US 61/939,110
PRIOR FILING DATE: 2014-02-12
NUMBER OF SEQ ID NOS: 111
SEQ ID NO 80
LENGTH: 446
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic: Antibody A-2(S101T) IgG1 heavy chain
Query Match 100.0%; Score 38; Length 446;
Best Local Similarity 85.7%;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1 AGXWFAY 7
|| ||||
Db 99 AGTWFAY 105
Prosecution Insights